These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33888445)

  • 1. A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease.
    Erickson A; Hayes A; Rajakumar T; Verrill C; Bryant RJ; Hamdy FC; Wedge DC; Woodcock DJ; Mills IG; Lamb AD
    Eur Urol Oncol; 2021 Jun; 4(3):358-369. PubMed ID: 33888445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
    Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.
    Cyrta J; Prandi D; Arora A; Hovelson DH; Sboner A; Rodriguez A; Fedrizzi T; Beltran H; Robinson DR; Gopalan A; True L; Nelson PS; Robinson BD; Mosquera JM; Tomlins SA; Shen R; Demichelis F; Rubin MA
    J Pathol; 2022 Jul; 257(3):274-284. PubMed ID: 35220606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.
    Parry MA; Srivastava S; Ali A; Cannistraci A; Antonello J; Barros-Silva JD; Ubertini V; Ramani V; Lau M; Shanks J; Nonaka D; Oliveira P; Hambrock T; Leong HS; Dhomen N; Miller C; Brady G; Dive C; Clarke NW; Marais R; Baena E
    Eur Urol Oncol; 2019 Feb; 2(1):1-11. PubMed ID: 30929837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of genetic markers in the management of prostate cancer.
    Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
    Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mutational landscape of prostate cancer.
    Barbieri CE; Bangma CH; Bjartell A; Catto JW; Culig Z; Grönberg H; Luo J; Visakorpi T; Rubin MA
    Eur Urol; 2013 Oct; 64(4):567-76. PubMed ID: 23759327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.
    Mahal BA; Gerke T; Awasthi S; Soule HR; Simons JW; Miyahira A; Halabi S; George D; Platz EA; Mucci L; Yamoah K
    Eur Urol Oncol; 2022 Feb; 5(1):18-29. PubMed ID: 34446369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal origin and spread of metastatic prostate cancer.
    Van Etten JL; Dehm SM
    Endocr Relat Cancer; 2016 Apr; 23(4):R207-17. PubMed ID: 27000662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
    Seibert TM; Garraway IP; Plym A; Mahal BA; Giri V; Jacobs MF; Cheng HH; Loeb S; Helfand BT; Eeles RA; Morgan TM
    Eur Urol; 2023 Mar; 83(3):241-248. PubMed ID: 36609003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
    Frank S; Nelson P; Vasioukhin V
    F1000Res; 2018; 7():. PubMed ID: 30135717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
    Ramnarine VR; Kobelev M; Gibb EA; Nouri M; Lin D; Wang Y; Buttyan R; Davicioni E; Zoubeidi A; Collins CC
    Eur Urol; 2019 Nov; 76(5):546-559. PubMed ID: 31445843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance.
    Liu A; Gao Y; Wang Q; Lin W; Ma Z; Yang X; Chen L; Xu D
    J Transl Med; 2023 Sep; 21(1):641. PubMed ID: 37726835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
    Sood A; Kishan AU; Evans CP; Feng FY; Morgan TM; Murphy DG; Padhani AR; Pinto P; Van der Poel HG; Tilki D; Briganti A; Abdollah F
    Eur Urol Oncol; 2024 Feb; 7(1):27-43. PubMed ID: 37423774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
    Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
    World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
    Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
    Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression.
    Sutcliffe P; Connock M; Shyangdan D; Court R; Kandala NB; Clarke A
    Health Technol Assess; 2013 Sep; 17(42):1-274. PubMed ID: 24070110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of ERG(+), EZH2, NKX3.1, and SPINK-1 subtypes to evaluate their association with clonal origin and disease progression in multifocal prostate cancer.
    Segura-Moreno YY; Sanabria-Salas MC; Mesa-López De Mesa JA; Varela-Ramirez R; Acosta-Vega NL; Serrano ML
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1728. PubMed ID: 36199157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.